The More Life Company Reports Rapid Systemic Delivery of USP Testosterone in Exploratory Quicksome™ Study

More Life Company reported results from an exploratory human pharmacokinetic study of USP-grade testosterone formulated with its patented Quicksome sublingual delivery technology. In the eight-participant study, testosterone showed rapid systemic appearance following Quicksome administration. The announcement is an early clinical-development datapoint, with no quantitative pharmacokinetic results or commercial timeline disclosed.

Analysis

This is not yet a valuation-relevant clinical catalyst. An eight-subject pharmacokinetic readout can establish formulation feasibility, but it provides no credible evidence on efficacy, safety, dose consistency, mucosal tolerability, adherence, manufacturing reproducibility, or the regulatory pathway required for a commercially differentiated testosterone product. Until the company discloses Cmax, Tmax, AUC, variability, comparator data, study design, and FDA engagement, the market should treat the release as promotional rather than independently verifiable de-risking.

The strategic hurdle is not proving rapid absorption; it is proving a clinically useful exposure profile versus cheap generic gels, injections, patches, and oral testosterone undecanoate. A rapid peak without durable, predictable exposure could worsen the principal commercial problem—physiologic hormone variability—and any meaningful clinical program would require substantially more capital than a microcap issuer can likely fund internally. Over the next 6-18 months, dilution risk, rather than intellectual-property value, is the more probable driver absent a disclosed licensing partner or a funded IND-enabling plan.

There is no clean liquid listed read-through among established testosterone franchises, and the signal is too weak to justify a directional sector trade. Contrarian upside would require data showing lower intra-patient PK variability and an exposure profile that avoids the administration burdens and labeling limitations of existing therapies; that could create licensing interest from AbbVie (ABBV), Endo (NDOI), or other men’s-health consolidators. The near-term asymmetry remains unfavorable because promotional microcap liquidity can amplify gains while fundamental confirmation is distant.

Key Decisions for Investors

• No position in MLCO/TMLCF at this stage; restrict to an event-driven watchlist given limited study size, likely low liquidity, and absent clinical/regulatory disclosures.
• Set an alert for full PK tables versus a marketed comparator, including Cmax, Tmax, AUC, half-life, and coefficient of variation. Only reassess long exposure if data demonstrate reproducible therapeutic-duration exposure and management identifies a funded FDA pathway or commercial partner.
• Treat any sharp price appreciation following this release as a potential liquidity-driven fade rather than confirmation of product value; avoid shorting unless borrow is available and daily liquidity supports execution.
• For a broader testosterone-therapy thesis, prefer profitable, liquid incumbents such as ABBV only after evidence of competitive displacement emerges; current information does not support a hedge or pair trade.